Cure4Cancer and the Bloomberg New Economy Cancer Coalition published its latest study in Cancer Discovery on the global access and participation in oncology clinical trials, a first of its kind analysis through a multi-stakeholder collaboration.
Sen. Jeanne Shaheen (D-NH) and Sen. Tammy Baldwin (D-WI) plan to introduce the Health Care Affordability Act of 2024, which would make permanent the Affordable Care Act enhanced tax credits that help make health insurance coverage affordable for an estimated 20 million people.
The University of Texas MD Anderson Cancer Center announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement. The journal will publish research, training program summaries, and quality improvement interventions for the oncology provider community.
Anthony Stack has joined Fox Chase Cancer Center as an assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.
Hilario Yankey joins Fox Chase Cancer Center as an assistant professor in the Department of Radiation Oncology.
Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Vulnerable patients facing social, environmental, and economic disadvantages often experience worse cancer outcomes than other groups. Some of these disparities may be reduced by increasing access to hospitals accredited by the American College of Surgeons Commission on Cancer, according to a study published in the Journal of the American College of Surgeons.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.
FDA approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.
FDA approved Tagrisso (osimertinib) in the U.S. for treatment of adult patients with unresectable, stage 3 epidermal growth factor receptor-mutated non-small cell lung cancer whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.
